Clinical Report: Comprehensive Multi-Omics Investigation in Atherosclerosis
Overview
This study identifies a distinct 14-metabolite profile associated with atherosclerosis (AS) and elucidates the interactions between microbiome, metabolites, and host factors. The findings suggest potential biomarkers and therapeutic targets for AS diagnosis and intervention.
Background
Atherosclerosis is a leading cause of cardiovascular diseases, characterized by complex metabolic and inflammatory processes. Understanding the interplay between host metabolism and gut microbiota is crucial for identifying novel biomarkers and therapeutic strategies. This study leverages high-throughput metabolomics and machine learning to explore these interactions in AS.
Data Highlights
Metabolite
Diagnostic Potential
Trimethylamine N-oxide
High
3-Hydroxyhippuric acid
High
Cholesteryl sulfate
High
Key Findings
A total of 122 differential metabolites were identified between AS patients and healthy controls.
14 overlapping metabolites demonstrated strong discriminative performance for AS diagnosis.
Key metabolites included Trimethylamine N-oxide, 3-Hydroxyhippuric acid, and Cholesteryl sulfate.
Despite limited differences in gut microbiota composition, significant correlations between specific genera and metabolites were observed.
Senescence markers P16 and P21 were significantly elevated in AS, correlating with key metabolites and microbial taxa.
Clinical Implications
The identified metabolite signature may serve as a valuable tool for early diagnosis and risk stratification in atherosclerosis. Clinicians should consider the integration of metabolomic data with traditional risk factors to enhance patient management strategies.
Conclusion
This comprehensive investigation highlights the importance of a coordinated microbiome–metabolite–host interaction network in atherosclerosis, paving the way for future research into targeted therapies and biomarkers.
